Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.

Authors:
Damiana TST; Paraïso P; de Ridder C; Stuurman D; Seimbille Y and 1 more

Journal:
Eur J Nucl Med Mol Imaging

Publication Year: 2023

DOI:
10.1007/s00259-023-06364-4

PMCID:
PMC10611828

PMID:
37584725

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur J Nucl Med Mol Imaging

Abbreviation: Eur J Nucl Med Mol Imaging

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nuclear Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Activated fibroblasts in muscle sarcoidosis revealed by [<sup>18</sup>F]FAPI-74 PET.
Watabe T; Fukusumi T; Inohara H and 7 more (2023) - Transparency Score: 3/6
Adoption of Lutetium-<sup>177</sup> PSMA radioligand therapy for metastatic castration resistant pr…
Flegar L; Thoduka SG; Librizzi D and 9 more (2023) - Transparency Score: 3/6
A machine learning tool to improve prediction of mediastinal lymph node metastases in non-small cel…
Rogasch JMM; Michaels L; Baumgärtner GL and 10 more (2023) - Transparency Score: 5/6
Analysis of image data from the EuroNet PHL-C2 trial indicates a potential reduction in injected F-…
Tran-Gia J; Eberlein U; Lassmann M and 10 more (2023) - Transparency Score: 3/6
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in adv…
Wild D; Grønbæk H; Navalkissoor S and 11 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approvalAll animal experiments were approved by the Animal Welfare Committee of the Erasmus MC, and all experiments were conducted in accordance to institutional guidelines. Competing interestSD receives financial support from Advanced Accelerator Applications, a Novartis Company, for an unrelated project. Competing interest SD receives financial support from Advanced Accelerator Applications, a Novartis Company, for an unrelated project."

Evidence found in paper:

"Funding This work was partly supported by NWO ZonMw Veni #09150161810061."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025